Antengene Corporation Limited
德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024

The board (the "**Board**") of directors (the "**Directors**") of Antengene Corporation Limited (the "**Company**" or "**Antengene**") is pleased to announce the unaudited condensed consolidated results of the Company and its subsidiaries (collectively, the "**Group**", "**we**" or "**us**") for the six months ended June 30, 2024 (the "**Reporting Period**"), together with comparative figures for the six months ended June 30, 2023. The consolidated financial statements of the Group for the Reporting Period have been reviewed by the audit committee of the Company (the "**Audit Committee**") and the Company's auditor.

FINANCIAL HIGHLIGHTS

	For the six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
	Unaudited	Unaudited
Revenue	**60,779**	72,016
Other income and gains	**27,317**	121,073
Research and development costs	**(130,841)**	(226,093)
Selling and distribution expenses	**(56,028)**	(88,246)
—Milestone payments related to APAC commercialization	**–**	*(21,286)*
Administrative expenses	**(58,478)**	(83,756)
Loss for the period	**(167,033)**	(218,694)
Adjusted loss for the period*	**(152,567)**	(189,437)
Adjusted loss for the period excluding net foreign exchange gain	**(158,748)**	(281,690)

* Adjusted loss for the period is not defined under the IFRS, it represents the loss for the period excluding the effect brought by equity-settled share-based payment expense.

IFRS Measures:

Our revenue decreased by RMB11.2 million from RMB72.0 million for the six months ended June 30, 2023 to RMB60.8 million for the six months ended June 30, 2024. In August 2023, we entered into a commercialization partnership with Hansoh Pharma for XPOVIO® (selinexor), which resulted in a temporary sales decline as there was a transition period following the partnership. In December 2023, XPOVIO® (selinexor) was successfully included in the 2023 NRDL, which led to a necessary price reduction. Through several months' recovery and sustained efforts, despite the price reduction and the necessary transition period, our revenue for the six months ended June 30, 2024 only experienced a decrease of 15.6% compared to that of for the six months ended June 30, 2023. This decrease was largely offset by a substantial increase in sales volume, demonstrating the successful transition of our business model and strong sales performance.

Our other income and gains decreased by RMB93.8 million from RMB121.1 million for the six months ended June 30, 2023 to RMB27.3 million for the six months ended June 30, 2024, primarily attributable to the decreased net foreign exchange gain.

Our research and development costs decreased by RMB95.3 million from RMB226.1 million for the six months ended June 30, 2023 to RMB130.8 million for the six months ended June 30, 2024, primarily attributable to our decreased R&D employee costs and drug development expenses as a result of enhanced R&D efficiency, and our decreased licensing fees.

Our selling and distribution expenses decreased by RMB32.2 million from RMB88.2 million for the six months ended June 30, 2023 to RMB56.0 million for the six months ended June 30, 2024, primarily attributable to the absence of milestone payments related to APAC commercialization in 2024 and the decreased selling and distribution expenses in Greater China market due to the commercialization partnership with Hansoh Pharma.

Our administrative expenses decreased by RMB25.3 million from RMB83.8 million for the six months ended June 30, 2023 to RMB58.5 million for the six months ended June 30, 2024, primarily attributable to the decreased employee costs.

As a result of the foregoing, the loss for the period decreased by RMB51.7 million from RMB218.7 million for the six months ended June 30, 2023 to RMB167.0 million for the six months ended June 30, 2024.

Non-IFRS Measures:

Loss for the period excluding the effect brought by equity-settled share-based payment expense decreased by RMB36.8 million from RMB189.4 million for the six months ended June 30, 2023 to RMB152.6 million for the six months ended June 30, 2024, primarily due to our decreased operating expenses, partially offset by our decreased net foreign exchange gain.

Adjusted loss for the period excluding net foreign exchange gain decreased significantly by RMB123.0 million from RMB281.7 million for the six months ended June 30, 2023 to RMB158.7 million for the six months ended June 30, 2024, representing a remarkable reduction of 43.7%, which was largely due to our well-performed cost efficiency strategy resulting in the decrease of our adjusted research and development costs, adjusted selling and distribution expenses and adjusted administrative expenses.

BUSINESS HIGHLIGHTS

During the Reporting Period, and as at the date of this announcement, significant advancement has been made with respect to our product pipeline and business operations:

COMMERCIALIZED ASSET:

– **Selinexor (ATG-010, XPOVIO®, Greater China brand name "希維奧®", first-in-class XPO1 inhibitor)**

- In June 2024, South Korea's National Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO® (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma (rrMM). XPOVIO® has officially been included into the national reimbursed drugs list of South Korea since July 1, 2024.

- In July 2024, China National Medical Products Administration (NMPA) has approved a new indication of XPOVIO® (selinexor) as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) after at least 2 lines of systemic therapy.

LATE-STAGE ASSET:

– **Onatasertib (ATG-008, mTORC1/2 inhibitor)**

- In May 2024, we announced the latest results from the Phase I/II TORCH-2 study. The results were subsequently presented in an Oral Presentation session at the 2024 American Society for Clinical Oncology Annual Meeting (ASCO 2024). ATG-008 combined with toripalimab (anti-PD-1 antibody) showed promising anti-tumor activity and acceptable tolerability in checkpoint inhibitor (CPI)-naïve cervical cancer patients, achieving an overall response rate (ORR) of 53.3% and a disease control rate (DCR) of 86.7%. In general, ATG-008 in combination with toripalimab are very well tolerated.

OTHER CLINICAL STAGE ASSETS:

– **ATG-101 (PD-L1/4-1BB bispecific antibody)**

- The Phase I trial of ATG-101 for the treatment of advanced/metastatic solid tumors and B-cell non-Hodgkin lymphoma (B-NHL) (the "**PROBE-CN trial**" and the "**PROBE trial**") are ongoing in mainland China, Australia, and the United States, respectively.

- In March 2024, the preclinical studies on ATG-101 were published in Cancer Research in a paper titled ATG-101 is a tetravalent PD-L1×4-1BB bispecific antibody that stimulates anti-tumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation.

– **ATG-037 (CD73 inhibitor)**

  • The Phase I trial of ATG-037 for the treatment of locally advanced or metastatic solid tumors (the "**STAMINA Trial**") is ongoing in mainland China and the United States.

– **ATG-022 (Claudin 18.2 antibody-drug conjugate)**

  • In March 2024, we initiated the Phase II part of CLINCH study of ATG-022 in China and Australia.

  • In June 2024, we announced the latest results from the Phase I CLINCH study. The results were subsequently presented as a poster at the ASCO 2024. As of October 9th, 2023, 10 patients have been enrolled, receiving doses ranging from 0.3 to 2.4 mg/kg. No dose-limiting toxicities (DLTs) were reported. Preliminary efficacy data among 7 gastric cancer patients across multiple doses in the Phase I dose escalation demonstrated one complete response (CR) in a patient with gastric cancer (2.4 mg/kg, CLDN 18.2-negative) and one partial response (PR) in another patient (1.8 mg/kg, CLDN 18.2 expression undetermined).

– **ATG-031 (anti-CD24 monoclonal antibody)**

  • The Phase I trial of ATG-031 for the treatment of advanced solid tumors or (the "**PERFORM trial**") is ongoing in the United States.

  • In June 2024, we announced the latest results from the Phase I PERFORM study. The results were subsequently presented as a poster at the ASCO 2024. As of April 2024, the study is underway in 4 sites in the United States, and the first dose level has been cleared.

PRE-CLINICAL STAGE ASSETS:

We made steady progress in our pre-clinical pipeline assets – ATG-042 (PRMT5-MTA inhibitor) and ATG-201 (CD19 x CD3 T cell engager).

Technology Platform:

We made steady progress in our novel "2+1" T cell engager platform AnTenGager™, which enables conditional T cell activation with reduced risk of cytokine release syndrome (CRS).

BUSINESS DEVELOPMENT AND OTHER KEY ACTIVITIES:

• Leveraging our combinatory and complementary R&D strategy and through our strong R&D capabilities and strategic approach in developing novel therapies, we continue to realize our vision of treating patients beyond borders and improving their lives in discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies.

• During the Reporting Period, we did not engage in any new business development activities. This decision was strategically aligned with our focus on advancing our core research and development initiatives. We remain vigilant and open to future business development opportunities that align with our strategic vision and objectives.

MANAGEMENT DISCUSSION AND ANALYSIS

OUR VISION

Our vision is to treat patients beyond borders and improve their lives by discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies.

OVERVIEW

Started operations in 2017, we are a commercial-stage Asia-Pacific ("**APAC**") biopharmaceutical company focused on innovative oncology medicines. We distinguish ourselves through our strong R&D capabilities and strategic approach to developing novel oncology therapies.

We have strategically designed and built an innovative research pipeline of 1 commercial stage product, 8 clinical and multiple pre-clinical stage programs focused on oncology and immunology. We employ a combinatory and complementary R&D strategy to maximise the potential of our pipeline assets which are synergistic to each other. We have obtained New Drug Applications (NDAs) approvals of XPOVIO® (selinexor) in mainland China, Australia, South Korea, Singapore, Hong Kong, China and Taiwan, China. We subsequently submitted NDAs for XPOVIO® (selinexor) to the Pharmaceutical Administration Bureau of Macau, China, Malaysian National Pharmaceutical Regulatory Agency, Thai Food and Drug Authority and the Indonesia National Agency of Drug and Food Control (BPOM) for the treatment of rrMM and rrDLBCL.

Product Pipeline

We have a pipeline of 10 drug candidates that focus on oncology and range from pre-clinical stage to late-stage clinical programs. The following table summarizes our pipeline and the development status. Each candidate in the regions noted in the chart below in the "Antengene Rights" column:



[1] Licensed from Karyopharm and Antengene has rights for Greater China (Mainland China, Hong Kong, Taiwan, Macau), Australia, New Zealand, South Korea, and the ASEAN Countries;
[2] Licensed from Celgene (BMS) and Antengene has rights for Greater China, South Korea, Singapore, Malaysia, Indonesia, Vietnam, Laos, Cambodia, the Philippines, Thailand and Mongolia;
[3] Licensed from OriginoIl and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-101;
[4] Most advanced trial status in Antengene territories and the trials are responsible by Antengene;
[5] Most advanced trial status in partner territories in the rest of the world and the trials are conducted by our licensing partners

* SADAL Study (DLBCL US Trial) approval is under the accelerated approval pathway; ** Investigator-initiated trials; R/R: relapsed/refractory; Hem/Onc: hematological malignancies and solid tumors; R-GDP: Rituximab, Gemcitabine, Dexamethasone & Cisplatin; GemOx: Gemcitabine, Oxaliplatin; ICE: Ifosfamide, Carboplatin, Etoposide

AU: Australia; CA: Canada; EU: Europe; IL: Israel; MY: Malaysia; SG: Singapore; SK: South Korea; TW: Taiwan; UK: United Kingdom; US: United States;

BUSINESS REVIEW

We have made steady progress with regard to our pipeline assets in the first half of 2024.

In June 2024, South Korea's NHIS has approved the reimbursement of XPOVIO® (selinexor) for the treatment of adult patients with rrMM in June 2024. XPOVIO® has been officially included into the national reimbursed drugs list of South Korea since July 1, 2024.

NMPA has approved a new indication of XPOVIO® (selinexor) as a monotherapy for the treatment of adult patients with rrDLBCL after at least 2 lines of systemic therapy in June 2024.

Commercial-stage Product

Selinexor (ATG-010, XPOVIO®, Greater China brand name "希維奧®", first-in-class XPO1 inhibitor)

XPOVIO® (selinexor), our first commercial-stage product, orally available selective inhibitor of nuclear export (SINE) compound being developed for the treatment of various hematological malignancies and solid tumors. We obtained exclusive rights from Karyopharm Therapeutics Inc. ("**Karyopharm**") for the development and commercialization of XPOVIO® (selinexor) in mainland China, Hong Kong, Taiwan, Macau, South Korea, Australia, New Zealand and ASEAN countries.

Our licensing partner, Karyopharm, obtained approval through the U.S. Food and Drug Administration (FDA)'s Accelerated Approval Program on July 3, 2019 for XPOVIO® (selinexor) in combination with low-dose dexamethasone for the treatment of adult patients with rrMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), at least two immunomodulatory agents (IMiDs) and an anti-CD38 monoclonal antibody (mAb).

On June 22, 2020, XPOVIO® (selinexor) received accelerated approval from the U.S. FDA for the treatment of adult patients with rrDLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. On December 18, 2020, the U.S. FDA approved XPOVIO® (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

In July 2021, through a priority review process, the Ministry of Food and Drug Safety (MFDS) of South Korea approved the Company's NDA for XPOVIO® (selinexor) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (penta-refractory); and as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma who have received at least two prior lines of treatment. In December 2021, we submitted supplemental new drug application (sNDA) to MFDS for XPOVIO® (selinexor) in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

In December 2021, XPOVIO® (selinexor) received conditional approval for marketing by the NMPA, in combination with dexamethasone for the treatment of adults with rrMM who have received prior therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

In May 2023, we have submitted NDAs for XPOVIO® (selinexor) to the Indonesia BPOM for the treatment of rrMM and rrDLBCL.

In June 2023, XPOVIO® (selinexor) in combination with bortezomib and dexamethasone (XVd) has been listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of adult patients with rrMM who have received at least one prior therapy.

In July 2023, the Department of Health, the Government of the HKSAR has approved an NDA for XPOVIO® (selinexor), in combination with dexamethasone (Xd), for the treatment of adult patients with rrMM who have received at least four prior therapies and whose disease is refractory to at least two PIs, two IMiDs, an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

In August 2023, Antengene and Hansoh Pharmaceutical Group Company Limited ("**Hansoh Pharma**", SEHK: 3692.HK) have entered into a collaboration agreement for the commercialization of XPOVIO® (selinexor) in mainland China. Under the terms of the agreement, Antengene will continue to be responsible for research and development, regulatory approvals and affairs, product supply, and distribution of XPOVIO® (selinexor), while Hansoh Pharma will be exclusively responsible for commercialization of XPOVIO® (selinexor) in mainland China. Antengene will receive up to RMB200 million of upfront payments, RMB100 million of which shall be received upon signing, and pursuant to the agreement and subject to the terms and conditions thereof, Antengene shall be eligible to receive up to RMB100 million of the remaining upfront payments, and up to RMB535 million in milestone payments from Hansoh Pharma. Antengene will continue to record revenues from sales of XPOVIO® (selinexor) in mainland China and Hansoh Pharma will charge a service fee to Antengene.

In December 2023, the Pharmaceutical Administration Bureau of Macau has approved an NDA for XPOVIO® (selinexor), in combination with dexamethasone (Xd), for the treatment of adult patients with rrMM who have received at least four prior therapies and whose disease is refractory to at least two PIs, two IMiDs, an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

In December 2023, XPOVIO® (selinexor) has been added to the National Reimbursement Drug List ("**NRDL**") for the treatment of adult patients with rrMM whose disease is refractory to at least one PIs, one IMiD, and an anti-CD38 mAb. The 2023 NRDL has officially taken effect from January 1, 2024.

We have obtained NDA approvals of XPOVIO® (selinexor) in mainland China, South Korea, Singapore, Australia, Taiwan, Hong Kong and Macau. XPOVIO® (selinexor) in combination with dexamethasone (Xd) and in combination with bortezomib and dexamethasone (XVd) are listed on the PBS in Australia for the treatment of adult patients with rrMM who have received at least four prior line of therapy and at least one prior line of therapy respectively. Moreover, XPOVIO® (selinexor) in combination with dexamethasone (Xd) for the treatment of adult patients with rrMM is included in the national reimbursed drugs list of South Korea. We have also submitted NDA for XPOVIO® (selinexor) to Malaysian National Pharmaceutical Regulatory Agency, Thai Food and Drug Authority and Indonesia BPOM.

Several late-stage clinical studies are underway for XPOVIO® (selinexor) in mainland China:

A Phase III registrational clinical trial in combination with bortezomib and low-dose dexamethasone in rrMM (the "**BENCH trial**").

A Phase II/III registrational clinical trial in combination with rituximab, gemcitabine dexamethasone cisplatin ("**R-GDP**") in rrDLBCL, which is part of the global pivotal trial (XPORT-DLBCL-030) led by Karyopharm, is ongoing in mainland China.

Late-stage Product Candidate

ATG-008 (onatasertib, mTORC1/2 inhibitor)

ATG-008 (onatasertib) – We obtained an exclusive license from Celgene Corporation for the development and commercialization of onatasertib in mainland China and selected APAC markets. We initiated a Phase I/II study of onatasertib in combination with toripalimab (anti-PD-1 antibody) in mainland China (TORCH-2 study).

In May 2024, we announced the latest results from the Phase I/II TORCH-2 study. The results were subsequently presented in an oral presentation session at ASCO 2024.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET ATG-008 (ONATASERTIB) SUCCESSFULLY.

Other Clinical Candidates

ATG-101 (PD-L1/4-1BB bispecific antibody) – We received Investigational New Drug (IND) approval from the NMPA for a Phase I study of ATG-101 in March 2022 and we dosed the first patient in August 2022 in mainland China. The dose-escalation studies are ongoing in Australia, China and the United States. In September 2022, ATG-101 has been granted an Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of pancreatic cancer.

ATG-037 (CD73 inhibitor) – We received the approval from the Human Research Ethics Committees (HREC) in Australia for the Phase I trial in February 2022 and dosed the first patient in June 2022. The NMPA has approved a Phase I trial of ATG-037 in November 2022 and dosed the first patient in July 2023. As of June 30, 2024, we have completed dose finding and initiated dose optimization of the STAMINA trial.

ATG-022 (Claudin 18.2 antibody-drug conjugate) – We received approval from the HREC in Australia to initiate a Phase I trial of ATG-022 in patients with advanced or metastatic solid tumors in December 2022 and dosed the first patient in March 2023 in Australia. We also received IND approval from the NMPA in March 2023 in patients with advanced or metastatic solid tumors and dosed the first patient in May 2023. In May 2023, ATG-022 has been granted two ODDs consecutively by the U.S. FDA for the treatment of gastric cancer and pancreatic cancer. The dose-expansion studies are ongoing in Australia and China. As of June 30, 2024, we have initiated the Phase II trial of ATG-022.

ATG-031 (CD24 antibody) – We received IND clearance from the U.S. FDA to initiate the Phase I PERFORM trial in patients with advanced solid tumors or B-NHL in May 2023 and dosed the first patient in December 2023. As of June 30, 2024, we have cleared the first dose level of the PERFORM trial.

Pre-clinical Candidates

ATG-042 (PRMT5-MTA inhibitor) – We are conducting pre-clinical studies to support IND/ Clinical Trial Authorisation (CTA) applications of ATG-042.

ATG-201 (CD19 x CD3 T cell engager) – We are conducting pre-clinical studies to support IND/ CTA applications of ATG-201.

Technology Platform

AnTenGager™ (T cell engager platform) – We are conducting pre-clinical studies for multiple AnTenGager-based T cell engagers.

RESEARCH AND DEVELOPMENT

We focus on R&D of therapeutic strategies for the treatment of cancer. We seek to optimize the drug development process of each of our assets to fully unlock their therapeutic potential and maximise their clinical and commercial value. We have adopted a differentiated combinatory and complementary R&D approach to build a pipeline of first/best-in-class assets with synergistic profiles.

As at June 30, 2024, we have 9 ongoing clinical studies in mainland China, the United States and Australia with 9 of our pipeline assets, including ATG-010 (selinexor, XPO1 inhibitor), ATG-008 (onatasertib, mTORC1/2 inhibitor), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-037 (CD73 inhibitor), ATG-022 (Claudin 18.2 antibody-drug conjugate) and ATG-031 (CD24 antibody). XPOVIO® (selinexor) has been added to the 2023 NRDL for the treatment of adult patients with rrMM whose disease is refractory to at least one PIs, one IMiD, and an anti-CD38 mAb. The 2023 NRDL has officially taken effect from January 1, 2024. NMPA has also approved a new indication of XPOVIO® (selinexor) as a monotherapy for the treatment of adult patients with rrDLBCL after at least 2 lines of systemic therapy in June 2024.

Our adjusted R&D costs (non-IFRS measure) were approximately RMB121.7 million and RMB207.7 million for the six months ended June 30, 2024 and 2023 respectively. As at June 30, 2024, we had filed 9 patent applications in mainland China, and 11 international applications under the Patent Cooperation Treaty (PCT) for material intellectual properties.

BUSINESS DEVELOPMENT

During the Reporting Period, we did not engage in any new business development activities. This decision was strategically aligned with our focus on advancing our core research and development initiatives. Our primary objective remains the progression of our existing pipeline of innovative therapies and the enhancement of our technological capabilities. We have allocated our resources and efforts towards critical projects that are pivotal to our long-term growth and success. This approach ensures that we maintain our commitment to delivering cutting-edge solutions in the biotech sector.

We believe that by concentrating on these priorities, we will be better positioned to achieve significant milestones and create value for our stakeholders. We remain vigilant and open to future business development opportunities that align with our strategic vision and objectives.

EVENTS AFTER THE REPORTING PERIOD

In August 2024, Malaysian National Pharmaceutical Regulatory Agency has approved a NDA for XPOVIO® (selinexor) for two indications: (1) in combination with bortezomib and dexamethasone for the treatment of adult patients with MM who have received at least one prior therapy; and (2) in combination with dexamethasone for the treatment of adult patients with MM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Data from the on-going Phase II CLINCH dose expansion study, as of August 21, shows that 21 CLDN18.2 positive gastric cancer patients have been treated with ATG-022. Among the 12 patients who at least underwent their first tumor assessment after study treatment, 5 achieved partial response (PR), resulting in an overall response rate (ORR) of 41.7% (including one patient with very low CLDN18.2 expression), and a disease control rate (DCR) of 100%. The Phase II CLINCH study is currently progressing smoothly in China and Australia.

FUTURE AND OUTLOOK

Leveraging our combinatory and complementary R&D strategy and through our strong R&D capabilities and strategic approach in developing novel therapies, we continue to realize our vision of treating patients beyond borders and improving their lives by discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies.

We will continue to advance the clinical development of our 9 clinical stage products in multiple therapeutic areas, and continue to implement our dual-engine approach of external partnerships and internal discovery to build up a pipeline focusing on the key oncogenic pathways, tumor microenvironment and tumor associated antigens globally and across the APAC region.

We have received NDA approvals for XPOVIO® (selinexor, ATG-010) in South Korea and China in 2021, approvals in Singapore, Australia and Taiwan in 2022, and approvals in Macau and Hong Kong in 2023. We have also received NDA approval for additional indication of DLBCL in China in 2024.

With the expected NDA approvals mentioned above and building upon our core commercial leadership team with experience in multiple successful launches of top hematology products globally, in APAC region and China in the past, we will continue to build out our commercial team in preparation for a first-in-class launch of XPOVIO® (selinexor) in APAC region to address unmet medical needs in our territories.

FINANCIAL INFORMATION

The Board announces the unaudited condensed consolidated results of the Group for the six months ended June 30, 2024, with comparative figures for the corresponding period in the previous year as follows:

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

		Six months ended June 30,	
		2024	2023
	Notes	***RMB'000***	*RMB'000*
		(Unaudited)	(Unaudited)
REVENUE	*4*	**60,779**	72,016
Cost of sales		**(8,856)**	(12,649)
Gross profit		**51,923**	59,367
Other income and gains	*4*	**27,317**	121,073
Research and development costs		**(130,841)**	(226,093)
Selling and distribution expenses		**(56,028)**	(88,246)
Administrative expenses		**(58,478)**	(83,756)
Other expenses		**(478)**	(571)
Finance costs		**(448)**	(468)
LOSS BEFORE TAX	*5*	**(167,033)**	(218,694)
Income tax expense	*6*	**–**	–
LOSS FOR THE PERIOD		**(167,033)**	(218,694)
Attributable to:			
Owners of the parent		**(167,033)**	(218,694)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	*8*		
Basic and diluted			
– For loss for the period		**RMB (0.27)**	RMB (0.36)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
LOSS FOR THE PERIOD	**(167,033)**	(218,694)
OTHER COMPREHENSIVE LOSS		
Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	**(1,209)**	(57,549)
OTHER COMPREHENSIVE LOSS FOR THE PERIOD, NET OF TAX	**(1,209)**	(57,549)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	**(168,242)**	(276,243)
Attributable to:		
Owners of the parent	**(168,242)**	(276,243)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Notes	**June 30, 2024** ***RMB'000*** **(Unaudited)**	December 31, 2023 *RMB'000* (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment		**259,754**	240,091
Right-of-use assets		**61,327**	66,493
Other intangible assets		**3,034**	3,365
Equity investments designated at fair value through other comprehensive income		**3,636**	3,636
Financial assets at fair value through profit or loss		**5,213**	5,181
Prepayments and other receivables		**15,773**	57,997
Total non-current assets		**348,737**	376,763
CURRENT ASSETS			
Inventories		**12,612**	15,266
Trade receivables	*9*	**30,121**	9,684
Prepayments and other receivables		**46,103**	29,066
Financial assets at fair value through profit or loss		**106**	105
Cash and bank balances		**1,023,682**	1,187,703
Total current assets		**1,112,624**	1,241,824
CURRENT LIABILITIES			
Trade payables	*10*	**3,360**	3,857
Other payables and accruals	*11*	**182,796**	179,766
Lease liabilities		**8,228**	7,265
Total current liabilities		**194,384**	190,888
NET CURRENT ASSETS		**918,240**	1,050,936
TOTAL ASSETS LESS CURRENT LIABILITIES		**1,266,977**	1,427,699
NON-CURRENT LIABILITIES			
Lease liabilities		**9,973**	13,755
Interest-bearing bank borrowings		**180,000**	180,000
Other non-current liabilities		**83,396**	86,560
Total non-current liabilities		**273,369**	280,315
Net assets		**993,608**	1,147,384
EQUITY			
Equity attributable to owners of the parent			
Share capital		**451**	451
Treasury shares		**(7,073)**	(7,073)
Reserves		**1,000,230**	1,154,006
Total equity		**993,608**	1,147,384

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

1 CORPORATE AND GROUP INFORMATION

The Company is a limited liability company incorporated in the Cayman Islands on August 28, 2018. The registered address of the Company is the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

The Company is an investment holding company. The subsidiaries of the Company were involved in the research, development and commercialisation of pharmaceutical products.

The shares of the Company have been listed on the Main Board of the Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") effective from November 20, 2020.

2.1 BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended June 30, 2024 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended December 31, 2023.

2.2 CHANGES IN ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended December 31, 2023, except for the adoption of the following revised International Financial Reporting Standards ("**IFRSs**") for the first time for the current period's financial information.

Amendments to IFRS 16	*Lease Liability in a Sale and Leaseback*
Amendments to IAS 1	*Classification of Liabilities as Current or Non-current* (the "**2020 Amendments**")
Amendments to IAS 1	*Non-current Liabilities with Covenants* (the "**2022 Amendments**")
Amendments to IAS 7 and IFRS 7	*Supplier Finance Arrangements*

The above amendments are not expected to have any significant impact on the Group's interim condensed consolidated financial information.

3 OPERATING SEGMENT INFORMATION

Operating segment information

For management purposes, the Group has only one reportable operating segment, which is the research, development and commercialisation of pharmaceutical products. Since this is the only reportable operating segment of the Group, no further operating segment analysis thereof is presented.

Geographical information

(a) Revenue from external customers

	Six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Greater China	**54,044**	67,255
Other countries/regions	**6,735**	4,761
Total revenue	**60,779**	72,016

The revenue information above is based on the locations of the customers.

(b) Non-current assets

	June 30,	December 31,
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Greater China	**332,753**	359,949
United States	**3,204**	3,775
Australia	**1,631**	2,093
Total non-current assets	**337,588**	365,817

The non-current asset information above is based on the locations of the assets and excludes financial instruments.

Information about major customers

Revenue from each of major customers, which accounted for 10% or more of the Group's revenue during the reporting period, is as follows:

	Six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Customer A	**53,569**	67,075

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	Six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue from contracts with customers	**60,779**	72,016

Revenue from contracts with customers

(a) Disaggregated revenue information

	Six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Types of goods		
Sales of pharmaceutical products	**60,779**	72,016
Geographical markets		
Greater China	**54,044**	67,255
Other countries/regions	**6,735**	4,761
Total revenue from contracts with customers	**60,779**	72,016
Timing of revenue recognition		
Goods transferred at a point in time	**60,779**	72,016

(b) Performance obligations

Information about the Group's performance obligations is summarised below:

Sales of pharmaceutical products

The performance obligation is satisfied upon delivery of the pharmaceutical products and payment is generally due within 60 to 150 days from the date of billing.

An analysis of other income and gains is as follows:

	Six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Other income		
Government grants*	**811**	14,662
Bank interest income	**20,292**	14,157
Other interest income from financial assets at fair value through profit or loss	**1**	1
Total other income	**21,104**	28,820
Other gains		
Foreign exchange gains, net	**6,181**	92,253
Changes in fair value of equity investments at fair value through profit and loss	**32**	–
Total gains	**6,213**	92,253
Total other income and gains	**27,317**	121,073

* Government grants include subsidies from the governments which are specifically for (i) the incentive and subsidies for research and development activities which are recognised upon compliance with the attached conditions; (ii) other government grants related to income that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Group with no future related costs recognised in profit or loss in the period in which they become receivable; and (iii) the capital expenditure incurred for plant and machinery and is recognised over the useful life of the related assets.

5 LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging/(crediting):

	Six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Cost of inventories sold	**8,856**	12,649
Depreciation of property, plant and equipment	**8,149**	7,992
Depreciation of right-of-use assets	**4,763**	7,450
Amortisation of other intangible assets	**334**	582
Lease payments not included in the measurement of lease liabilities	**1,498**	2,062
Employee benefit expense:		
Wages and salaries	**72,960**	129,376
Pension scheme contributions (defined contribution scheme)	**9,261**	20,211
Staff welfare expenses	**957**	1,845
Equity-settled share-based payment expense	**14,466**	29,257
	97,644	180,689
Foreign exchange differences, net**	**(6,181)**	(92,253)
Fair value gains on financial assets at fair value through profit and loss**	**(32)**	–
Loss on disposal of items of property, plant and equipment*	**43**	–

* Included in "Other expenses" in the consolidated statement of profit or loss

** Included in "Other income and gains" in the consolidated statement of profit or loss

6 INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Cayman Islands

Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. In addition, upon payments of dividends by the Company to its shareholders, no Cayman Islands withholding tax is imposed.

British Virgin Islands

Under the current laws of the British Virgin Islands ("**BVI**"), the subsidiaries incorporated in the BVI are not subject to tax on income or capital gains. In addition, upon payments of dividends by these subsidiaries to their shareholders, no BVI withholding tax is imposed.

Hong Kong

The subsidiaries incorporated in Hong Kong are subject to income tax at the rate of 16.5% (2023: 16.5%) on the estimated assessable profits arising in Hong Kong during the period, except for one subsidiary of the Group which is a qualifying entity under the two-tiered profits tax rates regime. The first HK$2,000,000 (2023: HK$2,000,000) of assessable profits of this subsidiary are taxed at 8.25% (2023: 8.25%) and the remaining assessable profits are taxed at 16.5% (2023: 16.5%).

Macau

The subsidiary incorporated in Macau is subject to income tax at the rate of 12% (2023: 12%) on the estimated assessable profits arising in Macau during the period.

Mainland China

Pursuant to the Corporate Income Tax Law of the People's Republic of China and the respective regulations (the "**CIT Law**"), the subsidiaries which operate in mainland China are subject to CIT at a rate of 25% (2023: 25%) on the taxable income.

Australia

No provision for Australia profits tax has been made as the Group had no assessable profits derived from or earned in Australia during the period (2023: Nil). The subsidiary incorporated in Australia is subject to income tax at the rate of 25% (2023: 25%) on the estimated assessable profits arising in Australia during the period.

Singapore

No provision for Singapore profits tax has been made as the Group had no assessable profits derived from or earned in Singapore during the period (2023: Nil). The subsidiaries incorporated in Singapore are subject to income tax at the rate of 17% (2023: 17%) on the estimated assessable profits arising in Singapore during the period.

South Korea

No provision for South Korea profits tax has been made as the Group had no assessable profits derived from or earned in South Korea during the period (2023: Nil). The subsidiary incorporated in South Korea is subject to income tax at the rate of 10% (2023: 10%) on the estimated assessable profits arising in South Korea during the period.

United States of America

The subsidiary incorporated in Delaware, the United States is subject to statutory United States federal corporate income tax at a rate of 21% (2023: 21%). It is also subject to the state income tax in Delaware at a rate of 8.7% (2023: 8.7%) during the period.

Taiwan

No provision for Taiwan profits tax has been made as the Group had no assessable profits derived from or earned in Taiwan during the period. The subsidiary incorporated in Taiwan is subject to income tax at the rate of 20% on the estimated assessable profits arising in Taiwan during the period.

No provision for income taxation has been made for the six months ended June 30, 2024 (June 30, 2023: Nil) as the Group had no assessable profits derived from the operating entities of the Group.

7 DIVIDENDS

No dividend was paid or declared by the Company during the six months ended June 30, 2024 (June 30, 2023: Nil).

8 LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amounts is based on the loss for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 618,974,062 (June 30, 2023: 614,876,787) in issue during the period.

No adjustment has been made to the basic loss per share amounts presented for the six months ended June 30, 2024 and 2023 in respect of a dilution as the impact of the share options and restricted share units outstanding had an anti-dilutive effect on the basic loss per share amounts presented.

The calculations of basic and diluted loss per share are based on:

	Six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss		
Loss attributable to ordinary equity holders of the parent, used in the basic and diluted loss per share calculation	**(167,033)**	(218,694)

	Number of shares	
	Six months ended June 30,	
	2024	2023
	(Unaudited)	(Unaudited)
Shares		
Weighted average number of ordinary shares in issue* during the period used in the basic and diluted loss per share calculation	**618,974,062**	614,876,787

* After considering treasury shares

9 TRADE RECEIVABLES

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	June 30,	December 31,
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 6 months	**30,061**	9,625
6 to 12 months	**60**	59
Total	**30,121**	9,684

10 TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	June 30, 2024 ***RMB'000*** **(Unaudited)**	December 31, 2023 *RMB'000* (Audited)
Within 3 months	**3,360**	3,857

The trade payables are non-interest-bearing and are normally settled on terms of two to three months.

11 OTHER PAYABLES AND ACCRUALS

	June 30, 2024 ***RMB'000*** **(Unaudited)**	December 31, 2023 *RMB'000* (Audited)
Amount due to related parties	**–**	38
Deferred income*	**23,657**	24,326
Payroll payables	**17,053**	31,636
Other tax payables	**12,023**	13,146
Payables for purchase of property, plant and equipment	**836**	1,943
Other payables**	**129,227**	108,677
Total	**182,796**	179,766

* As at June 30, 2024, deferred income of RMB23,657,000 (December 31, 2023: RMB24,326,000) represent the government grants related to an asset that will be recognised in profit or loss over the expected useful life of the relevant asset.

** Other payables primarily consist of accrued or invoiced but unpaid fees for services from contract research organisations ("**CROs**"), contract development manufacture organisations ("**CDMOs**") and clinical site management operators ("**SMOs**").

Other payables and accruals are unsecured, non-interest-bearing and repayable on demand. The carrying amounts of financial liabilities included in other payables and accruals as at the end of each reporting period approximate to their fair values due to their short-term maturities.

FINANCIAL REVIEW

	For the six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
REVENUE	**60,779**	72,016
Cost of sales	**(8,856)**	(12,649)
Gross profit	**51,923**	59,367
Other income and gains	**27,317**	121,073
Research and development costs	**(130,841)**	(226,093)
Selling and distribution expenses	**(56,028)**	(88,246)
Administrative expenses	**(58,478)**	(83,756)
Other expenses	**(478)**	(571)
Finance costs	**(448)**	(468)
LOSS BEFORE TAX	**(167,033)**	(218,694)
Income tax expense	**–**	–
LOSS FOR THE PERIOD	**(167,033)**	(218,694)
Non-IFRS measures:		
Adjusted loss for the period	**(152,567)**	(189,437)

Revenue. Our revenue decreased by RMB11.2 million from RMB72.0 million for the six months ended June 30, 2023 to RMB60.8 million for the six months ended June 30, 2024. In August 2023, we entered into a commercialization partnership with Hansoh Pharma for XPOVIO® (selinexor), aiming to leverage their well-established commercialization infrastructure to improve the efficiency, which resulted in a temporary sales decline as there was a transition period involved before a ramp up in sales. In December 2023, XPOVIO® (selinexor) was successfully included in the 2023 NRDL, which led to a necessary price reduction. Through several months' recovery and sustained efforts, despite the price reduction and the necessary transition period, our revenue for the six months ended June 30, 2024 only experienced a decrease of 15.6% compared to that of for the six months ended June 30, 2023. This decrease was largely offset by a substantial increase in sales volume, demonstrating the successful transition of our business model and strong sales performance. We remain confident that the NRDL inclusion, our collaboration with Hansoh Pharma, and continuous indication expansion potential of XPOVIO® (selinexor) will drive sustainable revenue growth in the future.

Other Income and Gains. Our other income and gains decreased by RMB93.8 million from RMB121.1 million for the six months ended June 30, 2023 to RMB27.3 million for the six months ended June 30, 2024, primarily attributable to the net foreign exchange gain of RMB6.2 million recorded for the six months ended June 30, 2024 due to the slight rise in the exchange rate of USD against RMB, but not as favourable as that of for the six months ended June 30, 2023 which recorded RMB92.3 million.

Research and Development Costs. Our research and development costs decreased by RMB95.3 million from RMB226.1 million for the six months ended June 30, 2023 to RMB130.8 million for the six months ended June 30, 2024. This decrease was primarily attributable to the combined impact of (i) a decrease of RMB49.9 million in R&D employee costs and drug development expenses as a result of enhanced R&D efficiency. This decrease reflected the strategic optimization of our R&D team and the streamlining of our pipeline, enabling us to concentrate investments on the assets with the greatest potential; and (ii) a decrease in licensing fees as we made no payments for the six months ended June 30, 2024, compared to the RMB40.5 million for the six months ended June 30, 2023 to acquire all the outstanding rights of ATG-037 from Calithera.

	For the six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
Employee costs	**51,327**	86,920
– Equity-settled share-based payment expense	***9,171***	*18,384*
Depreciation and amortization	**6,312**	6,837
Licensing fees	**–**	40,464
Drug development expenses	**62,479**	76,812
Professional fees	**7,574**	7,529
Others	**3,149**	7,531
Total	**130,841**	226,093

Selling and distribution expenses. Our selling and distribution expenses decreased by RMB32.2 million from RMB88.2 million for the six months ended June 30, 2023 to RMB56.0 million for the six months ended June 30, 2024. This decrease was primarily attributable to (i) the absence of milestone payments related to APAC commercialization for the six months ended June 30, 2024, resulting in a RMB21.3 million decrease; and (ii) a decrease of RMB10.6 million in selling and distribution expenses in Greater China market primarily due to the commercialization partnership with Hansoh Pharma, initiated in August 2023, which allowed us to leverage their market development expertise, significantly reducing our employee costs. Such decrease was partially offset by our increased market development expenses.

The table below sets forth the components of our selling and distribution expenses by nature for the periods indicated:

	For the six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
Milestone payments related to APAC commercialization	**–**	21,286
Subtotal	**–**	21,286
Employee costs	**12,603**	42,571
– Equity-settled share-based payment expense	***1,151***	*1,856*
Market development expenses	**42,729**	22,754
Depreciation and amortization	**317**	1,487
Others	**379**	148
Subtotal	**56,028**	66,960
Total	**56,028**	88,246

The table below sets forth the components of our selling and distribution expenses by geographical markets, excluding milestone payments related to APAC commercialization, for the periods indicated:

	For the six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
Greater China	**42,815**	53,369
Other countries/regions	**13,213**	13,591
Total	**56,028**	66,960

Administrative Expenses. Our administrative expenses decreased by RMB25.3 million from RMB83.8 million for the six months ended June 30, 2023 to RMB58.5 million for the six months ended June 30, 2024. This decrease was primarily attributable to the decreased employee costs as a reflection of our ongoing cost control efforts and the improved operation efficiency.

	For the six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
Employee costs	**33,714**	51,198
– Equity-settled share-based payment expense	***4,144***	*9,017*
Professional fees	**9,878**	13,516
Depreciation and amortization	**6,617**	7,700
Others	**8,269**	11,342
Total	**58,478**	83,756

NON-IFRS MEASURES

To supplement the Group's unaudited condensed consolidated financial statements, which are presented in accordance with the IFRS, the Company also uses adjusted loss for the period and other adjusted figures as additional financial measures, which are not required by, or presented in accordance with, the IFRS. The Company believes that these adjusted measures provide useful information to shareholders and potential investors in understanding and evaluating the Group's consolidated results of operations in the same manner as they help the Company's management.

Adjusted loss for the period represents the loss for the period excluding the effect of equity-settled share-based payment expense. The term adjusted loss for the period is not defined under the IFRS. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as substitute for analysis of, the Group's results of operations or financial condition as reported under IFRS. The Company's presentation of such adjusted figure may not be comparable to a similarly titled measure presented by other companies. However, the Company believes that this and other non-IFRS measures are reflections of the Group's normal operating results by eliminating potential impacts of items that the management do not consider to be indicative of the Group's operating performance, and thus, facilitate comparisons of operating performance from period to period and company to company to the extent applicable.

The table below sets forth a reconciliation of the loss to adjusted loss during the periods indicated:

	For the six months ended June 30,	
	2024	2023
	RMB'000	*RMB'000*
Loss for the period	**(167,033)**	(218,694)
Added:		
Equity-settled share-based payment expense	**14,466**	29,257
Adjusted loss for the period	**(152,567)**	(189,437)

EMPLOYEES AND REMUNERATION POLICIES

The following table sets forth a breakdown of our employees as at June 30, 2024 by function:

Function	**Number of employees**	**% of total number of employees**
General and Administrative	50	28.09
Research and Development	85	47.75
Commercialization	20	11.24
Manufacturing	23	12.92
Total	**178**	**100.00**

As at June 30, 2024, we had 149 employees in China and 29 employees in overseas. Our employees' remuneration comprises salaries, bonuses, employee provident fund and social security contributions and other welfare payments. In accordance with applicable Chinese laws, we have made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees.

Moreover, a wide range of on-the-job training and capacity-building activities were organized to help all employees to develop professional clinical knowledge and strengthen their management skills. To ensure our employees are well-equipped to deliver their work, we help new employees quickly fit into the Company by offering orientation training and on-the-job training from their entry so they can familiarize themselves with Antengene and their work duties. In addition, each new employee will also be assigned a mentor to help them adapt to the new working environment and explore their personal development and career aspirations.

LIQUIDITY AND FINANCIAL RESOURCES

As at June 30, 2024, our cash and bank balances were RMB1,023.7 million, as compared to RMB1,187.7 million as at December 31, 2023. The decrease was mainly due to the operating expenses for the six months ended June 30, 2024.

As at June 30, 2024, the Group's cash and bank balances were held mainly in USD and RMB.

As at June 30, 2024, the current assets of the Group were RMB1,112.6 million, including cash and bank balances of RMB1,023.7 million, and other current assets of RMB88.9 million. As at June 30, 2024, the current liabilities of the Group were RMB194.4 million, including other payables and accruals of RMB182.8 million and other current liabilities of RMB11.6 million.

Current Ratio

Current ratio is calculated using current assets divided by current liabilities and multiplied by 100%. As at June 30, 2024, our current ratio was 572.4% (as at December 31, 2023: 650.6%).

Gearing Ratio

Gearing ratio is calculated using total liabilities divided by total assets and multiplied by 100%. As at June 30, 2024, our gearing ratio was 32.0% (as at December 31, 2023: 29.1%).

OTHER FINANCIAL INFORMATION

Significant Investments, Material Acquisitions and Disposals

As at June 30, 2024, we did not hold any significant investments. For the six months ended June 30, 2024, we did not have material acquisitions or disposals of subsidiaries, associates and joint ventures.

Future Plans for Material Investments or Capital Assets

We did not have any concrete plans for material investments or capital assets as at June 30, 2024.

Foreign Exchange Risk

We have transactional currency exposures. The majority of our bank balances and interest receivables are denominated in foreign currencies and are exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Contingent Liabilities

As at June 30, 2024, we did not have any material contingent liabilities.

Pledge or charge of assets

As at June 30, 2024, the Group had a total of RMB43.0 million of the leasehold land pledged to secure its bank facilities.

CORPORATE GOVERNANCE AND OTHER INFORMATION

COMPLIANCE WITH CORPORATE GOVERNANCE CODE

The Company is committed to maintaining high standards of corporate governance to safeguard the interests of the shareholders of the Company (the "**Shareholders**") and to enhance corporate value and accountability. The Company has applied the principles and code provisions as set out in the Corporate Governance Code (the "**CG Code**") contained in Part 2 of Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). During the Reporting Period, the Board is of the opinion that the Company has complied with all the code provisions except for the deviation from code provision C.2.1 of the CG Code which is explained below.

Code provision C.2.1 of the CG Code provides that the roles of the chairman of the Board (the "**Chairman**") and chief executive officer (the "**CEO**") should be separated and should not be performed by the same individual. During the Reporting Period and as at the date of this announcement, the roles of the Chairman and CEO of the Company are held by Dr. Jay Mei ("**Dr. Mei**") who is a founder of the Company.

The Board believes that, in view of his experience, personal profile and his roles in the Company, Dr. Mei is the Director best suited to identify strategic opportunities and focus of the Board due to his extensive understanding of our business as the CEO. The Board also believes that the combined role of Chairman and CEO can promote the effective execution of strategic initiatives and facilitate the flow of information between the management of the Company and the Board.

In addition, the decisions to be made by the Board require approval by at least a majority of the Directors and that the Board comprises three executive Directors, one non-executive Director and three independent non-executive Directors, which the Company believes that there are sufficient checks and balances in the Board. Dr. Mei and other Directors are aware of and undertake to fulfill their fiduciary duties as Directors, which require, among other things, that they shall act for the benefit and in the best interest of the Company and will make decisions for the Group accordingly.

The Board will continue to review and consider splitting the roles of the Chairman and the CEO at the time when it is appropriate by taking into account the circumstances of the Group as a whole. Further information concerning the corporate governance practices of the Company will be set out in the corporate governance report in the annual report of the Company for the year ending December 31, 2024.

The Company will continue to regularly review and monitor its corporate governance practices to ensure compliance with the CG Code, and maintain a high standard of corporate governance practices of the Company.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF LISTED ISSUERS (THE "MODEL CODE")

The Company has adopted the Model Code contained in Appendix C3 to the Listing Rules as the guidelines for Directors' dealings in the securities of the Company. Specific enquiries have been made of all the Directors, and they have confirmed that they have complied with the required standards set out in the Model Code throughout the Reporting Period.

The Company's relevant employees, who are likely to be in possession of unpublished inside information of the Company, are also subject to the Model Code. No incident of non-compliance of the Model Code by the employees was noted by the Company throughout the Reporting Period.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (or sale of treasury shares) during the Reporting Period. As at June 30, 2024, the Company did not hold any treasury shares (as defined under the Listing Rules).

USE OF NET PROCEEDS

The shares of the Company were listed on the Main Board of the Stock Exchange on November 20, 2020 (the "**Listing Date**"). The Group received Net Proceeds (after deduction of underwriting commissions and related costs and expenses) from the IPO and the exercise of over-allotment option of approximately RMB2,274.70 million (the "**Net Proceeds**"). As of June 30, 2024, the total unutilized Net Proceeds amounted to approximately RMB508.35 million (the "**Unutilized Net Proceeds**").

The net proceeds from the listing (adjusted on a pro rata basis based on the actual net proceeds) have been and will be utilized in accordance with the purposes set out in the prospectus of the Company dated November 9, 2020 (the "**Prospectus**") and subsequently the announcement of the Company dated 22 March 2024 regarding the change in use of proceeds. The table below sets out the original and revised planned allocations of the Net Proceeds, the actual usage during the Reporting Period and the Unutilized Net Proceeds as at June 30, 2024:

Function	Original % of use of the Net Proceeds (Approximately)	Original allocation of the Net Proceeds *RMB million*	Revised % of use of the Net Proceeds[2] (Approximately)	Revised allocation of the Net Proceeds[2] *RMB million*	Revised allocation of the Unutilized Net Proceeds as at December 31, 2023[2] *RMB million*	Actual usage of the Net Proceeds during the Reporting Period *RMB million*	Unutilized Net Proceeds as at June 30, 2024 *RMB million*	Expected timeline for full utilization of the Unutilized Net Proceeds
Fund ongoing and planned clinical trials and milestone payments of our two Core Products and commercial launches of ATG-010	41.00%	932.63	41.00%	932.63	–	–	–	N/A
Fund ongoing and planned clinical trials and milestone payments of four other clinical-stage drug candidates in our pipeline	25.00%	568.67	5.16%	117.29	12.04	8.44	3.60	Expected to be fully utilized by December 31, 2025
Fund ongoing pre-clinical studies and planned clinical trials for other pre-clinical drug candidates in our pipeline	9.00%	204.72	33.35%	758.65	553.93	74.65	479.28	Expected to be fully utilized by December 31, 2025
For expansion of our pipeline, including discovery of new drug candidates and business development activities	14.00%	318.46	9.49%	215.91	36.13	10.66	25.47	Expected to be fully utilized by December 31, 2025
For capital expenditure	1.00%	22.75	1.00%	22.75	–	–	–	N/A
For general corporate purposes	10.00%	227.47	10.00%	227.47	–	–	–	N/A
Total	**100.00%**	**2,274.70**	**100.00%**	**2,274.70**	**602.10**	**93.75**	**508.35**	

Notes:

(1) Net proceeds from the IPO were received in HKD and translated into RMB for the allocation and the utilization calculation, and have been adjusted slightly due to the fluctuation of the foreign exchange rates since the listing.

(2) On March 22, 2024, the Board resolved to reallocate the Unutilized Net Proceeds of approximately RMB553.93 million as at December 31, 2023 to "Fund ongoing pre-clinical studies and planned clinical trials for other pre-clinical drug candidates in our pipeline". For more details about the reason of adjustment, please refer to the announcement of the Company dated March 22, 2024.

(3) The expected timeline was based on the Company's estimation of future market conditions and business operations, remains subject to change based on actual R&D progress, market conditions and business needs. The unutilized net proceeds of RMB508.35 million as at June 30, 2024 are expected to be fully utilized by December 31, 2025.

AUDIT COMMITTEE AND REVIEW OF INTERIM RESULTS

The Audit Committee has three members (who are all independent non-executive directors), being Mr. Sheng Tang (chairman), Dr. Rafael Fonseca and Ms. Jing Qian with written terms of reference in compliance with the Listing Rules.

The Audit Committee has considered and reviewed the accounting principles and practices adopted by the Group and discussed matters in relation to internal control and financial reporting with the management. The Audit Committee reviewed and considered that the interim financial results for the six months ended June 30, 2024 are in compliance with the relevant accounting standards, rules and regulations and appropriate disclosures have been duly made.

In addition, the Company's external auditor, Ernst & Young, has performed an independent review of the Group's interim financial information for the six months ended June 30, 2024 in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants.

PUBLIC FLOAT

According to the information that is publicly available to the Company and within the knowledge of the Board, at least 25% of the Company's total number of issued shares was held by the public at all times since the Listing Date and up to the date of this announcement as required under the Listing Rules.

MATERIAL LITIGATION

The Company was not involved in any material litigation or arbitration during the Reporting Period. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group as at June 30, 2024.

INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2024.

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This announcement is published on the websites of the Stock Exchange (**www.hkexnews.hk**) and the Company (**www.antengene.com**). The interim report for the six months ended June 30, 2024 containing all the information required by Appendix D2 to the Listing Rules will be published on the websites of the Stock Exchange and the Company in September 2024.

APPRECIATION

The Board would like to express its sincere gratitude to the Shareholders, management team, employees, business partners and customers of the Group for their support and contribution to the Group.

By the order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, China, August 23, 2024

As at the date of this announcement, the Board comprises Dr. Jay Mei, and Mr. Donald Andrew Lung as the executive Directors; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca, as the independent non-executive Directors.